Zealand Pharma Shares Suffer Record Decline Following Obesity Drug Trial Results
Shares in Danish biotechnology company Zealand Pharma experienced a dramatic collapse on Friday, plummeting more than 30 percent in early trading. This decline represents the company's worst trading day on record and follows the release of disappointing mid-stage clinical trial results for its obesity treatment, petrelintide.
Petrelintide Weight Loss Results Lag Behind Rival Treatments
The clinical trial, conducted in collaboration with pharmaceutical giant Roche, involved 493 participants over a 42-week period. Results showed that patients using petrelintide achieved weight loss of up to 10.7 percent of their body weight. While this demonstrates the drug's effectiveness in helping patients lose weight, it significantly trailed behind competing treatments in the rapidly expanding obesity drug market.
The most notable comparison comes from Eli Lilly's amylin-based drug, which achieved weight loss of up to 20.1 percent in a comparable mid-stage trial. This substantial performance gap contributed to investor disappointment and the subsequent market reaction.
Analyst Perspectives on Market Position
Financial analysts have offered mixed assessments of petrelintide's potential. Jefferies analysts noted that while the drug shows "potential for Wegovy-like efficacy," its "placebo-like tolerability does suggest this is a viable drug, though likely viewed as second-best to Lilly's elora for now." This assessment highlights the competitive challenges facing Zealand Pharma in a market increasingly dominated by more effective treatments.
The immediate market reaction was severe, with early trading losses wiping approximately 8.3 billion Danish crowns (equivalent to £960 million) from Zealand Pharma's market capitalisation. This dramatic valuation drop reflects investor concerns about the company's competitive position in the lucrative obesity treatment sector.
Broader Context of Obesity Drug Market Challenges
This development follows similar challenges faced by other pharmaceutical companies in the obesity treatment space. In February, shares in Novo Nordisk fell more than 15 percent in a single day after the company announced that its next-generation obesity drug CagriSema underperformed Eli Lilly's tirzepatide in clinical trials.
Novo Nordisk, which was valued at over $600 billion in 2024, has since lost approximately $400 billion in market capitalisation, returning its share price to levels last seen before the transformative success of its Wegovy obesity treatment. The company had specifically designed the CagriSema trial to demonstrate that the drug was at least as effective as tirzepatide in reducing weight, but ultimately failed to meet this goal.
Long-Term Implications for Market Competition
Analysts from J.P. Morgan have characterised the trial results as a significant setback that could potentially curb demand for CagriSema, temper long-term sales expectations, and leave Novo Nordisk struggling to regain market share in the fast-growing obesity treatment sector. They noted that "while CagriSema could offer a new treatment option to patients, the inferiority to Zepbound means it is unlikely to help Novo retake market share in obesity."
These developments highlight the intense competition and high stakes in the global obesity drug market, where even established pharmaceutical giants face significant challenges when their treatments fail to match the efficacy of rival products. The sector continues to attract substantial investment and research attention as obesity rates remain a pressing public health concern worldwide.
